Zambon S.p.A. and Valeo Pharma Inc. announce the approval of Onstryv® (safinamide) for the treatment of Parkinson’s Disease in Canada. Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality, sales and marketing, and distribution activities in Canada. Valeo Pharma expects the Canadian launch of safinamide to occur during the first half of 2019. Parkinson’s Disease is a progressive neurological disease involving the loss of dopamine-producing neurons in the brain. While tremors are the best-known symptom, Parkinson’s Disease also causes slowed movement, rigid muscles, impaired posture and balance, and speech and writing difficulties. An estimated 100,000 Canadians are affected, and the number of patients is expected to grow significantly over the next thirty years as the population continues to age.